<!DOCTYPE html><html lang="en-in"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1"><title>Publications - TAVIDoctor.com</title><meta name="description" content="Doctor Joy Shome is the co-author of 11 papers in leading Peer Reviewed Journals. He has also contributed 2 chapters to a canonical anthology of Cardiology Cases and articles to major medical publications."><meta name="generator" content="Publii Open-Source CMS for Static Site"><script type="gdpr-blocker/analytics" async src="https://www.googletagmanager.com/gtag/js?id=G-JVPKTHQCWH"></script><script type="gdpr-blocker/analytics">window.dataLayer = window.dataLayer || [];
				  function gtag(){dataLayer.push(arguments);}
				  gtag('js', new Date());
				  gtag('config', 'G-JVPKTHQCWH' );</script><link rel="canonical" href="https://tavidoctor.com/dr-joy-shome/publications/"><link rel="alternate" type="application/atom+xml" href="https://tavidoctor.com/feed.xml" title="TAVIDoctor.com - RSS"><link rel="alternate" type="application/json" href="https://tavidoctor.com/feed.json" title="TAVIDoctor.com - JSON"><meta property="og:title" content="Publications"><meta property="og:image" content="https://tavidoctor.com/media/website/original_cropped.png"><meta property="og:image:width" content="1952"><meta property="og:image:height" content="2104"><meta property="og:site_name" content="TAVIDoctor.com"><meta property="og:description" content="Doctor Joy Shome is the co-author of 11 papers in leading Peer Reviewed Journals. He has also contributed 2 chapters to a canonical anthology of Cardiology Cases and articles to major medical publications."><meta property="og:url" content="https://tavidoctor.com/publications/"><meta property="og:type" content="article"><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content="@tavidoctor"><meta name="twitter:title" content="Publications"><meta name="twitter:description" content="Doctor Joy Shome is the co-author of 11 papers in leading Peer Reviewed Journals. He has also contributed 2 chapters to a canonical anthology of Cardiology Cases and articles to major medical publications."><meta name="twitter:image" content="https://tavidoctor.com/media/website/original_cropped.png"><link rel="shortcut icon" href="https://tavidoctor.com/media/website/favicon-16x16.png" type="image/x-icon"><link rel="shortcut icon" href="https://tavidoctor.com/media/website/favicon-16x16.png" type="image/x-icon"><link rel="stylesheet" href="https://tavidoctor.com/assets/css/style.css?v=169f0ca1c15f8fdbf10fe30a560a1c24"><script type="application/ld+json">{"@context":"http://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://tavidoctor.com/dr-joy-shome/publications/"},"headline":"Publications","datePublished":"2025-03-26T23:14+05:30","dateModified":"2025-04-05T01:02+05:30","image":{"@type":"ImageObject","url":"https://tavidoctor.com/media/website/original_cropped.png","height":2104,"width":1952},"description":"Doctor Joy Shome is the co-author of 11 papers in leading Peer Reviewed Journals. He has also contributed 2 chapters to a canonical anthology of Cardiology Cases and articles to major medical publications.","author":{"@type":"Person","name":"Dr. Joy Shome","url":"https://tavidoctor.com/authors/dr-joy-shome/"},"publisher":{"@type":"Organization","name":"Dr. Joy Shome","logo":{"@type":"ImageObject","url":"https://tavidoctor.com/media/website/original_cropped.png","height":2104,"width":1952}}}</script><noscript><style>img[loading] {
                    opacity: 1;
                }</style></noscript><script src="https://kwesforms.com/v2/kf-script.js"></script><script>function diff_years(dt2, dt1) {
  var diff_secs = Math.abs(dt2 - dt1) / 1000;
  // Convert the difference from seconds to days
  var diff_days = diff_secs / (60 * 60 * 24);
  // Convert the days to years (approximate)
  var diff_years = Math.abs(Math.round(diff_days / 365.25));
  return diff_years;
}
    
function years_experience() {
  const pass_out_dt = new Date("Sep 1, 2004");
  const now_dt = Date.now();
  return diff_years(now_dt, pass_out_dt);
}
document.addEventListener('DOMContentLoaded', function() {
  // Hide call floating button in /contact page
  // Assumes div with id="Contact" is present
  if (document.getElementById("Contact")) {
    // fixedButton: See custom css, custom html-body
    document.getElementById("fixedButton").style.display = 'none';
  }
  
  // Populate correct yrs of exp
  const matches = document.querySelectorAll("span.joy_shome_experience_years");
  for (i = 0; i < matches.length; ++i) {
    matches[i].textContent = years_experience().toString();
  }
}, false);</script><body class="page-template"><div id="fixedButton"><a href="/contact" class="btn--white btn rounded"><img alt="ðŸ“ž" class="spin" src="/media/files/doctor-consultation.png"> <span>Consult Now</span></a></div><div class="container"><header class="header"><a href="https://tavidoctor.com/" class="logo"><img src="https://tavidoctor.com/media/website/original_cropped.png" alt="TAVIDoctor.com" width="1952" height="2104"></a><nav class="navbar js-navbar"><button class="navbar__toggle js-toggle" aria-label="Menu">Menu</button><ul class="navbar__menu"><li class="active-parent has-submenu"><a href="https://tavidoctor.com/" target="_self" aria-haspopup="true">Dr Joy Shome</a><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://tavidoctor.com/dr-joy-shome/clinical-experience/" target="_self">Clinical Experience</a></li><li><a href="https://tavidoctor.com/dr-joy-shome/education/" title="Education" target="_self">Education</a></li><li class="active-parent invert has-submenu"><a href="#" target="_self" aria-haspopup="true">Researchï¸™</a><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://tavidoctor.com/dr-joy-shome/conferences/" target="_self">Conferences</a></li><li class="active"><a href="https://tavidoctor.com/dr-joy-shome/publications/" target="_self">Publications</a></li><li><a href="https://tavidoctor.com/dr-joy-shome/tavi-trials/" target="_self">TAVI/TAVR Trials</a></li></ul></li><li class="invert has-submenu"><a href="#" target="_self" aria-haspopup="true">Popular Mediaï¸™</a><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://tavidoctor.com/dr-joy-shome/videos/" target="_self">Videos</a></li><li><a href="https://tavidoctor.com/dr-joy-shome/interviews/" target="_self">Press</a></li></ul></li></ul></li><li><a href="https://tavidoctor.com/cardiology/" target="_self">Cardiology</a></li><li class="has-submenu"><a href="https://tavidoctor.com/blog/" target="_self" aria-haspopup="true">Doctor&#x27;s Blog</a><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://tavidoctor.com/first-sapien-3-ultra-resilia-thv-at-morriston/" title="First Sapien Ultra Resilia THV (Transcatheter Heart Valve) procedure at Swansea Bay" target="_self">1st Sapien Ultra Resilia</a></li><li><a href="https://tavidoctor.com/no1-tavi-centre-in-2023/" target="_self">2023 #1 TAVI centre</a></li><li><a href="https://tavidoctor.com/blog/memories/" target="_self">Memories</a></li></ul></li><li><a href="https://tavidoctor.com/contact/" target="_self">Contact</a></li></ul></nav><div class="search"><div class="search__overlay js-search-overlay"><form action="https://tavidoctor.com/search.html" class="search__form"><input class="search__input" type="search" name="q" placeholder="search TAVIDoctor.com ..." aria-label="search TAVIDoctor.com ..."> <button type="submit" class="search__button"><span>Submit</span></button></form></div><button class="search__btn js-search-btn" aria-label="Search"><svg role="presentation" focusable="false" height="16" width="16"><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#search"/></svg></button></div></header><main class="main page"><article class="content"><header class="content__inner content__header"><h1 class="content__title">Publications</h1></header><div class="content__inner"><div class="content__entry"><p class="align-left dropcap">Doctor Joy Shome is the co-author of 11 papers in leading Peer Reviewed Journals. He has also contributed 2 chapters to a canonical anthology of Cardiology Cases and articles to major medical publications.</p><figure class="post__image"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/BJC-30-years-logo.svg" alt="The British Journal of Cardiology" width="386" height="100"></figure><figcaption><a href="https://bjcardio.co.uk/" target="_blank" rel="noopener noreferrer">The British Journal of Cardiology</a></figcaption></figure><h5 class="align-center">Vol. 32 - 14 Jan 2025</h5><p class="align-left"><a href="https://bjcardio.co.uk/2025/01/predictors-of-requirement-for-urgent-versus-elective-tavi-and-comparison-of-short-and-medium-outcomes/" target="_blank" rel="noopener noreferrer">Predictors of requirement for urgent versus elective TAVI and comparison of short and medium outcomes</a></p><pre class="p3">Previous studies have shown mixed results comparing short-term mortality in patients undergoing urgent transcatheter aortic valve implantation (Urg-TAVI) compared with elective procedures (El-TAVI) for severe aortic stenosis (AS). This study aimed to explore the predictors of requirement for Urg-TAVI versus El-TAVI, as well as compare differences in short- and intermediate-term mortality.<br><br>This single-centre, retrospective cohort study investigated 358 patients over three years. Baseline demographic data were collected for patients undergoing elective and urgent procedures, and mortality outcomes at one-month, one-year and three-year follow-up were compared.<br><br>Urg-TAVI was required in 131 (36.6%) patients. Patients undergoing Urg-TAVI were significantly more likely to be female, have poor left ventricular (LV) function, with higher baseline creatinine and higher clinical frailty score (CFS). Higher rates of vascular complications were independently associated with increased mortality at one month. Mortality at one year was associated with higher creatinine level (odds ratio [OR] 1.01, 95% confidence interval [CI] 1.00 to 1.01, p=0.0013) and an urgent procedure (OR 2.25, 95%CI 1.28 to 3.97, p=0.0048). There remained a higher mortality in the urgent patients at three-year follow-up.<br><br>In conclusion, undergoing TAVI urgently did not have a statistically significant effect on 30-day mortality. However, over long-term follow-up of one year, it was associated with worse mortality than elective TAVI, and this persisted out to three years.</pre><hr><figure class="post__image"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-03-28-at-1.24.03-PM.png" alt="The American Journal of Cardiology Â®" width="303" height="100" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-xl.png 1600w"></figure><figcaption><a href="https://www.ajconline.org/" target="_blank" rel="noopener noreferrer">The American Journal of Cardiology Â®</a></figcaption></figure><h5 class="align-center">Vol. 222 - 1 JulÂ  2024</h5><p class="align-left"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0002914924003217">Transcatheter Aortic Valve Replacement With the Navitor System: Real-World United Kingdom Experience</a></p><pre>The Navitor transcatheter <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/heart-valve" title="Learn more about heart valve from ScienceDirect's AI-generated Topic Pages" class="topic-link">heart valve</a>Â (THV) is the latest iteration of theÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/percutaneous-aortic-valve" title="Learn more about Portico from ScienceDirect's AI-generated Topic Pages" class="topic-link">Portico</a>Â self-expanding valve system. Early prospective studies have shown promising outcomes, however, there is a lack of complementary â€˜real-worldâ€™ data. This study aimed to assess early safety and efficacy outcomes of the Navitor THV using registry data from 6 high-volume United KingdomÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/percutaneous-aortic-valve-replacement" title="Learn more about transcatheter aortic valve replacement from ScienceDirect's AI-generated Topic Pages" class="topic-link">transcatheter aortic valve replacement</a>Â (TAVR) centers. Demographic, procedural, and in-hospital outcome data were retrieved from 6 United Kingdom centers. The primary safety end point was 30-day mortality. Primary efficacy end points were procedural success, mean aortic gradient, and â‰¥moderateÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/paravalvular-leak" title="Learn more about paravalvular leak from ScienceDirect's AI-generated Topic Pages" class="topic-link">paravalvular leak</a>. Secondary end points included rates of newÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/permanent-pacemaker" title="Learn more about permanent pacemaker from ScienceDirect's AI-generated Topic Pages" class="topic-link">permanent pacemaker</a>Â implantation, stroke, andÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-vessel-injury" title="Learn more about vascular injury from ScienceDirect's AI-generated Topic Pages" class="topic-link">vascular injury</a>. A total of 574 patients (mean age 83.4 years; 54.5% female) underwent Navitor TAVR between January 2020 and May 2023. The 30-day mortality in this patient cohort was 1.6%. Procedural success was 98.1%, mean echo-derived gradient post-TAVR was 7.7 Â± 4.8 mm Hg (95% confidence interval [CI] 7.2 to 8.3, p &lt;0.001) and 5.1% of patients had â‰¥moderateÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/paravalvular-leak" title="Learn more about paravalvular leak from ScienceDirect's AI-generated Topic Pages" class="topic-link">paravalvular leak</a>Â (sample proportion estimate [pÌ‚] = 0.051, 95% CI [0.035, 0.073], p &lt;0.001). New permanentÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/pacemaker-implantation" title="Learn more about pacemaker implantation from ScienceDirect's AI-generated Topic Pages" class="topic-link">pacemaker implantation</a>Â to discharge was required in 11% (pÌ‚ = 0.119, 95% CI 0.088 to 0.158, p &lt;0.001), stroke occurred in 1.2% of patients (pÌ‚ = 0.017, 95% CI 0.006 to 0.036, p &lt;0.001) and significantÂ <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-vessel-injury" title="Learn more about vascular injury from ScienceDirect's AI-generated Topic Pages" class="topic-link">vascular injury</a>Â in 1.6% (pÌ‚ = 0.014, 95% CI 0.005 to 0.032, p &lt;0.001). In conclusion, early procedural outcomes with Navitor TAVR compare favorably to new-generation THVs. Procedural success was high with a low incidence of complications.</pre><hr><figure class="post__image post__image--center"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/logo-1177270501.png" alt="Future Cardiology" width="224" height="120" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/logo-1177270501-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/logo-1177270501-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/logo-1177270501-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/logo-1177270501-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/logo-1177270501-xl.png 1600w"></figure><figcaption><p><span class="title">Future Cardiology</span></p></figcaption></figure><h5 class="align-center">Vol. 19(6) - 14 Jul 2023</h5><p class="align-left"><a href="https://www.tandfonline.com/doi/full/10.2217/fca-2023-0058">Predictors of 1- and 12-Month Mortality in Bifurcation Coronary Intervention: A Contemporary Perspective</a></p><pre><strong>Aim:</strong> Bifurcation-PCI is performed frequently, although without extensive evidence to back up a definitive solution for its complexity. We set out to identify factors associated with 1- and 12-month mortality after bifurcation-PCI between 2017 and 2021 in our tertiary center in Wales, UK.<br><strong><br>Results:</strong> Of 732 bifurcation PCI cases (mean age 69; 25% female), 67% were in ACS, 42% were left main PCI and 25.3% involved two-stent strategy. 30-day and 12-month mortality were 1.9 and 8.2%, respectively. Age, diabetes, smoking and renal failure are associated with mortality after bifurcation-PCI, while the choice between provisional and 2-stent strategies did not impact mortality/TLR.<br><br><strong>Conclusion:</strong>Â Awareness of â€˜real-worldâ€™ outcomes of bifurcation-PCI should be used for appropriate patient selection, technique planning and procedural consent.</pre><hr><figure class="post__image post__image--center align-center"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/jpm-logo.webp" alt="Journal of Personalized Medicine (JPM)" width="400" height="86" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/jpm-logo-xs.webp 384w, https://tavidoctor.com/media/posts/7/responsive/jpm-logo-sm.webp 600w, https://tavidoctor.com/media/posts/7/responsive/jpm-logo-md.webp 768w, https://tavidoctor.com/media/posts/7/responsive/jpm-logo-lg.webp 1200w, https://tavidoctor.com/media/posts/7/responsive/jpm-logo-xl.webp 1600w"></figure><figcaption>Journal of Personalized Medicine (JPM)</figcaption></figure><h5 class="align-center">Vol. 12(7) - 28 Jun 2022</h5><p class="align-left"><a href="https://www.mdpi.com/2075-4426/12/7/1056">Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study</a></p><pre><strong>Background</strong>: Data to support the routine use of embolic protection devices for stroke prevention during transcatheter aortic valve replacement (TAVR) are controversial. Identifying patients at high risk for peri-procedural cerebrovascular events may facilitate effective patient selection for embolic protection devices during TAVR.<br><br><strong>Aim</strong>: To generate a risk score model for stratifying TAVR patients according to peri-procedural cerebrovascular events risk.<br><br><strong>Methods and results:</strong>Â A total of 8779 TAVR patients from 12 centers worldwide were included. Peri-procedural cerebrovascular events were defined as an ischemic stroke or a transient ischemic attack occurring â‰¤24 h from TAVR. The peri-procedural cerebrovascular events rate was 1.4% (<span class="html-italic">n</span>Â = 127), which was independently associated with 1-year mortality (hazards ratio (HR) 1.78, 95% confidence interval (CI) 1.06â€“2.98,Â <span class="html-italic">p</span>Â &lt; 0.028). The TASK risk score parameters were history of stroke, use of a non-balloon expandable valve, chronic kidney disease, and peripheral vascular disease, and each parameter was assigned one point. Each one-point increment was associated with a significant increase in peri-procedural cerebrovascular events risk (OR 1.96, 95% CI 1.56â€“2.45,Â <span class="html-italic">p</span>Â &lt; 0.001). The TASK score was dichotomized into very-low, low, intermediate, and high (0, 1, 2, 3â€“4 points, respectively). The high-risk TASK score group (OR 5.4, 95% CI 2.06â€“14.16,Â <span class="html-italic">p</span> = 0.001) was associated with a significantly higher risk of peri-procedural cerebrovascular events compared with the low TASK score group.<br><br><strong>Conclusions:</strong>Â The proposed novel TASK risk score may assist in the pre-procedural risk stratification of TAVR patients for peri-procedural cerebrovascular events.</pre><hr><figure class="post__image post__image--center align-center"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/ehjcimaging_title1210667358.svg" alt="The European Heart Journal: Cardiovascular Imaging" width="500" height="75"></figure><figcaption><a href="https://www.escardio.org/Journals/ESC-Journal-Family/European-Heart-Journal-Cardiovascular-Imaging" target="_blank" rel="noopener noreferrer">The European Heart Journal: Cardiovascular Imaging</a></figcaption></figure><h5 class="align-center">Vol. 23(6) - 28 Jun 2021</h5><p class="align-left"><a href="https://academic.oup.com/ehjcimaging/article/23/6/811/6310334" target="_blank" rel="noopener noreferrer">2D high resolution vs. 3D whole heart myocardial perfusion cardiovascular magnetic resonance</a></p><div class="sec"><pre class="title"><strong>Aims</strong><br>Developments in myocardial perfusion cardiovascular magnetic resonance (CMR) allow improvements in spatial resolution and/or myocardial coverage. Whole heart coverage may provide the most accurate assessment of myocardial ischaemic burden, while high spatial resolution is expected to improve detection of subendocardial ischaemia. The objective of this study was to compare myocardial ischaemic burden as depicted by 2D high resolution and 3D whole heart stress myocardial perfusion in patients with coronary artery disease.<br><br><strong style="font-family: var(--editor-font-family); font-size: inherit;">Methods and results<br></strong><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">Thirty-eight patients [age 61â€‰Â±â€‰8 (21% female)] underwent 2D high resolution (spatial resolution 1.2 mm</span><sup style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-weight: var(--font-weight-normal);">2</sup><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">) and 3D whole heart (in-plane spatial resolution 2.3 mm</span><sup style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-weight: var(--font-weight-normal);">2</sup><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">) stress CMR at 3-T in randomized order. Myocardial ischaemic burden (%) was visually quantified as perfusion defect at peak stress perfusion subtracted from subendocardial myocardial scar and expressed as a percentage of the myocardium. Median myocardial ischaemic burden was significantly higher with 2D high resolution compared with 3D whole heart [16.1 (2.0â€“30.6) vs. 13.4 (5.2â€“23.2),Â </span><em style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">P</em><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">â€‰=â€‰0.004]. There was excellent agreement between myocardial ischaemic burden (intraclass correlation coefficient 0.81;Â </span><em style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">P</em><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">â€‰&lt;â€‰0.0001), with mean ratio difference between 2D high resolution vs. 3D whole heart 1.28â€‰Â±â€‰0.67 (95% limits of agreement âˆ’0.03 to 2.59). When using a 10% threshold for a dichotomous result for presence or absence of significant ischaemia, there was moderate agreement between the methods (Îºâ€‰=â€‰0.58,Â </span><em style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">P</em><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">â€‰&lt;â€‰0.0001).<br></span><strong style="font-family: var(--editor-font-family); font-size: inherit;"><br>Conclusion<br></strong><span style="color: var(--text-primary-color); font-family: var(--editor-font-family); font-size: inherit; font-weight: var(--font-weight-normal);">2D high resolution and 3D whole heart myocardial perfusion stress CMR are comparable for detection of ischaemia. 2D high resolution gives higher values for myocardial ischaemic burden compared with 3D whole heart, suggesting that 2D high resolution is more sensitive for detection of ischaemia.</span></pre></div><hr><figure class="post__image post__image--center align-center"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/3-s2.0-C20160026414-cov200h.gif" alt="Structural Heart Cases: A Color Atlas of Pearls and Pitfalls, 1st Edition" width="156" height="200"></figure><figcaption><a href="https://shop.elsevier.com/books/structural-heart-cases/sorajja/978-0-323-54695-9" target="_blank" rel="noopener noreferrer">Structural Heart Cases: A Color Atlas of Pearls and Pitfalls, 1st Edition</a></figcaption></figure><h5 class="align-center">Book Chapters - May 9, 2018</h5><p class="align-left">Chapters:</p><address>41. <a href="https://www.sciencedirect.com/science/article/abs/pii/B9780323546959000433" target="_blank" rel="noopener noreferrer">Transcatheter Valve Placement in a Mitral Ring</a></address><address>92. <a href="https://www.sciencedirect.com/science/article/abs/pii/B9780323546959000949" target="_blank" rel="noopener noreferrer">A Very Difficult Case of Valve-in-Valve Therapy</a></address><hr><figure class="post__image"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-03-28-at-1.24.03-PM.png" alt="The American Journal of Cardiology Â®" width="303" height="100" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.24.03-PM-xl.png 1600w"></figure><figcaption><a href="https://www.ajconline.org/" target="_blank" rel="noopener noreferrer">The American Journal of Cardiology Â®</a></figcaption></figure><h5 class="align-center">Vol. 119 - 1 May 2017</h5><p class="align-left"><a href="https://www.ajconline.org/article/S0002-9149(17)30120-0/abstract">Usefulness of Cardiac Magnetic Resonance Imaging to Measure Left Ventricular Wall Thickness for Determining Risk Scores for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy</a></p><pre>Echocardiography-derived measurements of maximum left ventricular (LV) wall thickness are important for both the diagnosis and risk stratification of hypertrophic cardiomyopathy (HC). Cardiac magnetic resonance (CMR) imaging is increasingly being used in the assessment of HC; however, little is known about the relation between wall thickness measurements made by the 2 modalities. We sought to compare measurements made with echocardiography and CMR and to assess the impact of any differences on risk stratification using the current European Society of Cardiology guidelines. Maximum LV wall thickness measurements were recorded on 50 consecutive patients with HC. Sixty-nine percent of LV wall thickness measurements were recorded with echocardiography, compared with 69% from CMR (p &lt;0.001). There was poor agreement on the location of maximum LV wall thickness; weighted-Cohen's Îº 0.14 (p = 0.036) and maximum LV wall thicknesses were systematically higher with echocardiography than with CMR (mean 19.1 Â± 0.4 mm vs 16.5 Â± 0.3 mm, p &lt;0.01, respectively); Bland-Altman bias 2.6 mm (95% confidence interval âˆ’9.8 to 4.6). Interobserver variability was lower for CMR (R<sup>2</sup>Â 0.67 echocardiography, R<sup>2</sup>Â 0.93 CMR). The mean difference in 5-year sudden cardiac death (SCD) risk between echocardiography and CMR was 0.49 Â± 0.45% (pÂ = 0.37). When classifying patients (low, intermediate, or high risk), 6 patients were reclassified when CMR was used instead of echocardiography to assess maximum LV wall thickness. These findings suggest that CMR measurements of maximum LV wall thickness can be cautiously used in the current European Society of Cardiology risk score calculations, although further long-term studies are needed to confirm this.</pre><hr><figure class="post__image"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-03-28-at-1.32.21-PM.png" alt="Journal of Cardiovascular Magnetic Resonance" width="632" height="78" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-xl.png 1600w"></figure><figcaption><a href="https://jcmr-online.biomedcentral.com/" target="_blank" rel="noopener noreferrer"><span class="c-journal-title__text">Journal of Cardiovascular Magnetic Resonance</span></a></figcaption></figure><h5 class="align-center">Vol. 19 - 5 Dec 2016</h5><p class="align-left"><a href="https://link.springer.com/article/10.1186/s12968-017-0381-3">Diagnostic performance of image navigated coronary CMR angiography in patients with coronary artery disease</a></p><pre class="c-article__sub-heading" data-test="abstract-sub-heading"><strong>Background</strong><br>The use of coronary MR angiography (CMRA) in patients with coronary artery disease (CAD) remains limited due to the long scan times, unpredictable and often non-diagnostic image quality secondary to respiratory motion artifacts. The purpose of this study was to evaluate CMRA with image-based respiratory navigation (iNAV CMRA) and compare it to gold standard invasive x-ray coronary angiography in patients with CAD.<br><br><strong>Methods</strong><br>Consecutive patients referred for CMR assessment were included to undergo iNAV CMRA on a 1.5Â T scanner. Coronary vessel sharpness and a visual score were assigned to the coronary arteries. A diagnostic reading was performed on the iNAV CMRA data, where a lumen narrowing &gt;50% was considered diseased. This was compared to invasive x-ray findings.<br><br><strong>Results</strong><br>Image-navigated CMRA was performed in 31 patients (77% male, 56Â Â±Â 14Â years). The iNAV CMRA scan time was 7Â min:21Â sÂ Â±Â 0Â min:28Â s. Out of a possible 279 coronary segments, 26 segments were excluded from analysis due to stents or diameter less than 1.5Â mm, resulting in a total of 253 coronary segments. Diagnostic image quality was obtained for 98% of proximal coronary segments, 94% of middle segments, and 91% of distal coronary segments. The sensitivity and specificity was 86% and 83% per patient, 80% and 92% per vessel and 73% and 95% per segment.<br><br><strong>Conclusion</strong><br>In this study, iNAV CMRA offered a very good diagnostic performance when compared against invasive x-ray angiography. Due to the short and predictable scan time it can add clinical value as a part of a comprehensive CAD assessment protocol.</pre><hr><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/15498719-1605885820470.webp" alt="Microcirculation journal" width="650" height="74" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/15498719-1605885820470-xs.webp 384w, https://tavidoctor.com/media/posts/7/responsive/15498719-1605885820470-sm.webp 600w, https://tavidoctor.com/media/posts/7/responsive/15498719-1605885820470-md.webp 768w, https://tavidoctor.com/media/posts/7/responsive/15498719-1605885820470-lg.webp 1200w, https://tavidoctor.com/media/posts/7/responsive/15498719-1605885820470-xl.webp 1600w"><figcaption><em>Microcirculation - The official journal of the Microcirculatory Society Inc., the Australia &amp; New Zealand Microcirculation Society, and the Japanese Society for Microcirculation</em></figcaption></figure><h5 class="align-center">Vol. 24(1) - 15 Dec 2016</h5><p class="align-left"><a href="https://onlinelibrary.wiley.com/doi/10.1111/micc.12340" target="_blank" rel="noopener noreferrer">Current perspectives in coronary microvascular dysfunction</a></p><pre>The coronary arterial system consists of large epicardial coronary arteries, pre-arterioles, and arterioles, which together closely regulate CBF. Structural, functional, and extravascular abnormalities of the microcirculation lead to CMD. CMD can present with symptoms suggestive of CAD, often in the absence of significant obstructive epicardial CAD. Conventional invasive angiography does not allow direct visualization of the microcirculation. Invasive indices, such as CBF and CFR, and non-invasive imaging modalities, such as CMR and PET, can be used to quantify absolute MBF and enable a direct and accurate assessment of coronary microvascular function. CMD appears to be more prevalent in women, typically presenting with symptoms of ischemia with unobstructed coronary arteries, and has a relatively unfavorable prognosis. CMD is classified clinically depending on the presence or absence of epicardial CAD, myocardial disease, or iatrogenic causes. Although invasive intracoronary techniques can be used to detect CMD, these cannot provide insight into the mechanisms involved in its pathogenesis. Imaging modalities such as CMR and cardiac PET are becoming indispensable tools in the evaluation of suspected CMD.</pre><hr><figure class="post__image"><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-03-28-at-1.32.21-PM.png" alt="Journal of Cardiovascular Magnetic Resonance" width="632" height="78" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-03-28-at-1.32.21-PM-xl.png 1600w"></figure><figcaption><div class="u-container"><div class="c-journal-header__inner"><p id="journalTitle" class="c-journal-title"><a href="https://jcmr-online.biomedcentral.com/" target="_blank" rel="noopener noreferrer"><span class="c-journal-title__text">Journal of Cardiovascular Magnetic Resonance</span></a></p></div></div></figcaption></figure><h5 class="align-center">Vol. 18 - 6 Jan 2016</h5><p class="align-left"><a href="https://www.sciencedirect.com/science/article/pii/S1097664723061677">Combined high-resolution assessment of quantitative perfusion and late enhancement. Towards accurate estimation of the ischaemic burden in patients with coronary artery disease</a></p><pre><strong><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit;">Background</span></strong><br><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/cardiac-magnetic-resonance-imaging" title="Learn more about Cardiac magnetic resonance from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">Cardiac magnetic resonance</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">Â (CMR) allows the combined evaluation ofÂ </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/heart-muscle-perfusion" title="Learn more about myocardial perfusion from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">myocardial perfusion</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">Â status and viability in the same examination. Novel methods for high-resolution quantiative analysis of myocardial perfusion have rencently been described. High-resolution perfusion avoids spatial averaging and potentially enables a more accurate assessment of total inducible ischaemic burden. The simultaneous analysis of high-resolution lateÂ </span><a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gadolinium" title="Learn more about gadolinium from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">gadolinium</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">Â enhancement images (LGE) allows excluding areas with overt ischaemic scar from quantitative perfusion analysis. This is potentially relevant to the estimation of the ischaemic burden, since areas of scar have can result in false-positive perfusion findings. The aim of this study was to test the feasibility of combined high-resolution assessment of perfusion and late enhancement, and to assess the potential of this novel approach to provide a more accurate estimation of the ischaemic burden in patients withÂ </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/coronary-artery-disease" title="Learn more about coronary artery disease from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">coronary artery disease</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">.<br><br><strong>Methods</strong></span><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);"><span style="color: #02192b;"><strong><br></strong></span></span><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">20 patients with known CAD and previous myocardial infarct referred for stress perfusion CMR due to new onset of angina were included. All patients underwent rest and adenosine stress first-pass perfusion at 3T (Philips Achieva) using a high-resolution kt turbo field echo sequence and a dual bolus approach (0.075 mmol of Gd/kg of body weight; Gadovist). LGE images were acquired 15 minutes after the rest injection of Gd. Quantiative perfusion analysis was performed using validated high-resolution deconvolution analysis. LGE analysis was performed using conventional semi-quantitative analysis (signal threshold of 5 standard deviations). Stress and rest </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/heart-muscle-blood-flow" title="Learn more about myocardial blood flow from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">myocardial blood flow</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">Â (MBF),Â </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/heart-muscle-perfusion" title="Learn more about myocardial perfusion from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">myocardial perfusion</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);"> reserve (MPR) and total LV ischaemic burden (MPR threshold of 1.5) were calculated with an without accounting for the presence of LGE and results compared.<br><br><strong>Results</strong><br></span><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);">All patients had LGE (scarred area 12.5 Â± 5.7%). Before considering LGE, average stress MBF, rest MBF and MPR were 2.39 Â± 0.94, 0.94 Â± 0.42 and 2.83 Â± 2.24, respectively. In areas of viableÂ </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/myocardium" title="Learn more about myocardium from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-family: var(--font-serif); font-size: inherit; font-weight: var(--font-weight-normal);">myocardium</a><span style="font-family: var(--font-serif); color: var(--text-primary-color); font-size: inherit; font-weight: var(--font-weight-normal);"> (LGE-), stress MBF, rest MBF and MPR were 2.82 Â± 0.69,1.01 Â± 0.26 (p = 0.01) and 3.25 Â± 0.58, respectively. In areas of scar (LGE+), stress MBF, rest MBF and MPR were 1.02 Â± 0.57,0.99 Â± 0.74(p = ns) and 1.04 Â± 0.63 (p = 0.001 vs LGE-), respectively. The overall ischaemic burden (at a MPR threshold of 1.5) was 21.3 Â± 12.5%. When excluding areas with LGE, the ischaemic burden was 13.4 Â± 6.7%(p = 0.001).<br><br><strong>Conclusions</strong><br></span><span style="font-size: inherit; color: var(--text-primary-color); font-weight: var(--font-weight-normal); font-family: var(--font-serif);">This study demonstrates the feasibility of combined high-resolution assessment of quantitative perfusion and late enhancement. Areas of scar did not show any hyperhaemic flow during adenosine stress (MPR of approximately 1). When a threshold of 1.5 is used to define the ischaemic burden, these areas would incorrectly be ascribed to areas of inducible </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/ischemia" title="Learn more about ischaemia from ScienceDirect's AI-generated Topic Pages" class="topic-link" style="font-size: inherit; font-weight: var(--font-weight-normal); font-family: var(--font-serif);">ischaemia</a><span style="font-size: inherit; color: var(--text-primary-color); font-weight: var(--font-weight-normal); font-family: var(--font-serif);">Â if correction for the presence of LGE is not used. Combined high-resolution assessment of quantitative perfusion and late enhancement has the potential to provide more accurate assessment of myocardial perfusion status.</span></pre><hr><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-04-03-at-3.10.34-AM.png" alt="Hospital Healthcare Europe - Clinical News, Views &amp; Research" width="375" height="100" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.10.34-AM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.10.34-AM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.10.34-AM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.10.34-AM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.10.34-AM-xl.png 1600w"><figcaption><a href="https://hospitalhealthcare.com/" target="_blank" rel="noopener noreferrer"><span class="EKtkFWMYpwzMKOYr0GYm LQVY1Jpkk8nyJ6HBWKAk">Hospital Healthcare Europe - Clinical News, Views &amp; Research</span></a></figcaption></figure><h5 class="align-center">Article - 14 May 2015</h5><p class="align-left"><a href="https://hospitalhealthcare.com/clinical/cardiovascular/treating-coronary-chronic-total-occlusions/" target="_blank" rel="noopener noreferrer">Treating coronary chronic total occlusions</a></p><pre>Significant advances in chronic total occlusion treatment have led to technical success rates approaching 90% with an overall complication rate that is no higher than conventional PCI</pre><hr><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/showCoverImage.jpeg" alt="The Journal of Obstetrics and Gynaecology" width="110" height="142" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/showCoverImage-xs.jpeg 384w, https://tavidoctor.com/media/posts/7/responsive/showCoverImage-sm.jpeg 600w, https://tavidoctor.com/media/posts/7/responsive/showCoverImage-md.jpeg 768w, https://tavidoctor.com/media/posts/7/responsive/showCoverImage-lg.jpeg 1200w, https://tavidoctor.com/media/posts/7/responsive/showCoverImage-xl.jpeg 1600w"><figcaption><a href="https://www.tandfonline.com/journals/ijog20" target="_blank" rel="noopener noreferrer">The Journal of Obstetrics and Gynaecology</a></figcaption></figure><h5 class="align-center">Letters to the Editor - 4 Jun 2012</h5><p class="align-left"><a href="https://www.tandfonline.com/doi/full/10.3109/01443615.2012.666583" target="_blank" rel="noopener noreferrer">Simple treatment options exist for supraventricular tachycardia in pregnancy</a></p><hr><figure class="post__image post__image--center"><figure class="post__image"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/Screenshot-2025-04-03-at-3.23.23-AM.png" alt="QJM: Quarterly Journal of Medicine - An International Journal of Medicine - By the Association of Physicians of Great Britain &amp; Ireland" width="486" height="100" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.23.23-AM-xs.png 384w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.23.23-AM-sm.png 600w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.23.23-AM-md.png 768w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.23.23-AM-lg.png 1200w, https://tavidoctor.com/media/posts/7/responsive/Screenshot-2025-04-03-at-3.23.23-AM-xl.png 1600w"></figure><figcaption>QJM: Quarterly Journal of Medicine - An International Journal of Medicine</figcaption></figure><h5 class="align-center">Vol 105(9) - 7 Jun 2012</h5><p class="align-left"><a href="https://academic.oup.com/qjmed/article-abstract/105/9/855/1552809" target="_blank" rel="noopener noreferrer">Oxygen use for chest pain in coronary care units across the UK</a></p><pre class="chapter-para"><strong>Aim:</strong>Â To quantify the adherence to national guidance for the use of oxygen in patients presenting with chest pain to coronary care units (CCUs) across the UK.<br><br><strong>Design:</strong>Â Prospective survey.<br><br><strong>Methods:</strong>Â A total of 307 hospitals were contacted by telephone between August 2010 and October 2010. Of these, 48 had no CCUs, 10 units refused to take part and 18 hospitals were contacted on 2 occasions but were unable to provide the information due to paucity of time owing to heavy clinical workload. Overall 231 hospitals participated in the audit questionnaire.<br><br><strong>Results:</strong>Â A total of 30% of the units used oxygen titrated to saturations in accordance with national guidelines. There was no difference between units that had on-site availability of percutaneous coronary intervention and those that did not. Those hospitals where there was a policy for routine oxygen prescription were as unlikely to comply with the guidelines on oxygen use as hospitals where oxygen was not routinely prescribed.<br><br><strong>Conclusion:</strong>Â Only one-third of CCUs in the UK reported adherence to guidelines with regards to oxygen delivery in patients presenting with chest pain. Despite this figure seeming rather low, this is consistent with practice through a range of specialties and guidelines. The evidence base for the oxygen guidance remains insecure. Additional research is required but in the meantime we recommend oxygen is prescribed according to current guidelines.</pre><hr><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/15408159-1600808650580.webp" alt="Pacing and Clinical Electrophysiology (PACE) Journal" width="600" height="69" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/15408159-1600808650580-xs.webp 384w, https://tavidoctor.com/media/posts/7/responsive/15408159-1600808650580-sm.webp 600w, https://tavidoctor.com/media/posts/7/responsive/15408159-1600808650580-md.webp 768w, https://tavidoctor.com/media/posts/7/responsive/15408159-1600808650580-lg.webp 1200w, https://tavidoctor.com/media/posts/7/responsive/15408159-1600808650580-xl.webp 1600w"><figcaption><a href="https://onlinelibrary.wiley.com/journal/15408159" target="_blank" rel="noopener noreferrer">Pacing and Clinical Electrophysiology (PACE) Journal</a></figcaption></figure><h5 class="align-center">Vol. 36(2) - 21 Jan 2011</h5><p class="align-left"><a href="https://onlinelibrary.wiley.com/doi/10.1111/j.1540-8159.2010.03021.x" target="_blank" rel="noopener noreferrer">Single Site Left Ventricular Pacing induced Dyssynchrony and Cardiomyopathy</a></p><pre>Single site left ventricular (LV) pacing in the absence of intrinsic ventricular activity can be as detrimental to LV function as right ventricular apical pacing. This report describes a patient with complete heart block who developed significant dyssynchrony and cardiomyopathy secondary to single site lateral LV pacing. The process was reversed by placement of a second anterior LV lead.</pre><hr><figure class="post__image post__image--center"><img decoding="async" loading="lazy" src="https://tavidoctor.com/media/posts/7/proceedings_of-the-nutrition-society.jpg" alt="Proceedings of the Nutrition Society Logo" width="180" height="240" sizes="(min-width: 37.5em) 1600px, 80vw" srcset="https://tavidoctor.com/media/posts/7/responsive/proceedings_of-the-nutrition-society-xs.jpg 384w, https://tavidoctor.com/media/posts/7/responsive/proceedings_of-the-nutrition-society-sm.jpg 600w, https://tavidoctor.com/media/posts/7/responsive/proceedings_of-the-nutrition-society-md.jpg 768w, https://tavidoctor.com/media/posts/7/responsive/proceedings_of-the-nutrition-society-lg.jpg 1200w, https://tavidoctor.com/media/posts/7/responsive/proceedings_of-the-nutrition-society-xl.jpg 1600w"><figcaption><a href="https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society" target="_blank" rel="noopener noreferrer">Proceedings of the Nutrition Society</a></figcaption></figure><h5 class="align-center">Vol. 67 (OCE3) - May 2008</h5><p><a href="https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/direct-percutaneous-endoscopic-jejunostomy-for-jejunal-feeding/FE1AEFC91C4C01ED6431F1DB9FDDE797" target="_blank" rel="noopener noreferrer">Direct percutaneous endoscopic jejunostomy for jejunal feeding</a></p><pre><strong>Aim:</strong> The aim was to review our experience of direct percutaneous endoscopic jejunostomy (DPEJ) tube placement at Aintree Centre for Gastroenterology, University Hospital Aintree, Liverpool (UHA).<br><br><strong>Conclusion:</strong> DPEJ can be performed with high success rates and a low rate of complications. This confirms its place as an alternative means of long-term enteral nutrition in patients for whom PEG is contraindicated or impossible. Complication rates were similar to those described in other series and the re-intervention rate was lower than commonly reported for PEG jejunal extensions.</pre><hr><p>Â </p></div></div></article></main><footer class="footer"><div class="footer__left"><ul class="footer__nav"><li><span>Profile Links -</span></li><li><a href="https://www.pcronline.com/Physicians/Joy-Shome" class="invert" title="PCROnline Profile of Dr Joy Shome" target="_blank">PCROnline</a></li><li><a href="https://kclpure.kcl.ac.uk/portal/en/persons/joy-shome-2" class="invert" target="_blank">King&#x27;s College</a></li></ul><div class="footer__copy">Powered by Publii</div></div><div class="footer__right"><div class="footer__social"><a href="https://www.facebook.com/joy.s.shome/" aria-label="Facebook" class="facebook"><svg><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#facebook"/></svg> </a><a href="https://x.com/tavidoctor" aria-label="Twitter" class="twitter"><svg><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#twitter"/></svg> </a><a href="https://www.linkedin.com/in/joy-saibal-shome/" aria-label="LinkedIn" class="linkedin"><svg><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#linkedin"/></svg> </a><a href="https://www.youtube.com/@tavidoctor" aria-label="Youtube" class="youtube"><svg><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#youtube"/></svg></a></div></div><button onclick="backToTopFunction()" id="backToTop" class="footer__bttop" aria-label="Back to top" title="Back to top"><svg><use xlink:href="https://tavidoctor.com/assets/svg/svg-map.svg#toparrow"/></svg></button></footer></div><script>window.publiiThemeMenuConfig = { mobileMenuMode: 'sidebar', animationSpeed: 300, submenuWidth: 'auto', doubleClickTime: 500, mobileMenuExpandableSubmenus: true, relatedContainerForOverlayMenuSelector: '.navbar', };</script><script defer="defer" src="https://tavidoctor.com/assets/js/scripts.min.js?v=9c5ab7a87221183f149a42b3cceb7956"></script><script>function publiiDetectLoadedImages () {
         var images = document.querySelectorAll('img[loading]:not(.is-loaded)');
         for (var i = 0; i < images.length; i++) {
            if (images[i].complete) {
               images[i].classList.add('is-loaded');
               images[i].parentNode.classList.remove('is-img-loading');
            } else {
               images[i].addEventListener('load', function () {
                  this.classList.add('is-loaded');
                  this.parentNode.classList.remove('is-img-loading');
               }, false);
            }
         }
      }
      publiiDetectLoadedImages();</script><div class="pcb" data-behaviour="badge" data-behaviour-link="#cookie-settings" data-revision="1" data-config-ttl="300" data-debug-mode="false"><div role="dialog" aria-modal="true" aria-hidden="true" aria-labelledby="pcb-title" aria-describedby="pcb-txt" class="pcb__banner"><div class="pcb__inner"><div id="pcb-title" role="heading" aria-level="2" class="pcb__title">This website uses cookies</div><div id="pcb-txt" class="pcb__txt">Select which cookies to opt-in to via the checkboxes below; our website uses cookies to examine site traffic and user activity while on our site, for marketing, and to provide search and social media functionality.</div><div class="pcb__buttons"><button type="button" class="pcb__btn pcb__btn--link pcb__btn--configure" aria-haspopup="dialog">Manage preferences</button> <button type="button" class="pcb__btn pcb__btn--solid pcb__btn--accept">Accept all</button></div></div></div><div class="pcb__popup" role="dialog" aria-modal="true" aria-hidden="true" aria-labelledby="pcb-popup-title"><div class="pcb__popup__wrapper"><div class="pcb__inner pcb__popup__inner"><div class="pcb__popup__heading"><div id="pcb-popup-title" role="heading" aria-level="2" class="pcb__title">Cookie settings</div><button class="pcb__popup__close" aria-label="Close"></button></div><div class="pcb__popup__content"><div class="pcb__txt pcb__popup__txt">We use cookies to enhance your browsing experience, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.</div><ul class="pcb__groups"><li class="pcb__group"><details><summary class="pcb__group__title">Required</summary><p class="pcb__group__txt">Cookies included in this group are essential for the basic functionality of the site, but do not collect any personally-identifiable data.</p></details><div class="pcb__popup__switch is-checked"><input type="checkbox" data-group-name="" id="pcb-group-0" checked="checked"> <label for="pcb-group-0">Required</label></div></li><li class="pcb__group"><details><summary class="pcb__group__title">Functionality</summary><p class="pcb__group__txt">This group is for cookies that add functionality to the website, such as cookies from Google which are necessary for the search plugin</p></details><div class="pcb__popup__switch"><input type="checkbox" data-group-name="functionality" id="functionality-cookies"> <label for="functionality-cookies">Functionality</label></div></li><li class="pcb__group"><details><summary class="pcb__group__title">Analytics</summary><p class="pcb__group__txt">This group refers to any cookies that collect analytical or tracking data for the purpose of providing statistics to the site owner</p></details><div class="pcb__popup__switch"><input type="checkbox" data-group-name="analytics" id="analytics-cookies"> <label for="analytics-cookies">Analytics</label></div></li><li class="pcb__group"><details><summary class="pcb__group__title">Marketting</summary><p class="pcb__group__txt">This group is for cookies that collect data that will be used for marketing purposes such as showing specific adverts to visitors, or allowing them to sign-up for newsletters or other communications.</p></details><div class="pcb__popup__switch"><input type="checkbox" data-group-name="marketting" id="marketting-cookies"> <label for="marketting-cookies">Marketting</label></div></li><li class="pcb__group"><details><summary class="pcb__group__title no-desc">Comments</summary></details><div class="pcb__popup__switch"><input type="checkbox" data-group-name="comments" id="comments-cookies"> <label for="comments-cookies">Comments</label></div></li></ul></div><div class="pcb__buttons pcb__popup__buttons"><button type="button" class="pcb__btn pcb__btn--solid pcb__btn--accept">Accept all</button> <button type="button" class="pcb__btn pcb__btn--reject">Reject all</button> <button type="button" class="pcb__btn pcb__btn--save">Save settings</button></div></div></div></div><div class="pcb__overlay" aria-hidden="true"></div><button class="pcb__badge" aria-label="Cookie Policy" aria-hidden="true"><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" width="40" height="40" viewBox="0 0 23 23" fill="currentColor"><path d="M21.41 12.71c-.08-.01-.15 0-.22 0h-.03c-.03 0-.05 0-.08.01-.07 0-.13.01-.19.04-.52.21-1.44.19-2.02-.22-.44-.31-.65-.83-.62-1.53a.758.758 0 0 0-.27-.61.73.73 0 0 0-.65-.14c-1.98.51-3.49.23-4.26-.78-.82-1.08-.73-2.89.24-4.49.14-.23.14-.52 0-.75a.756.756 0 0 0-.67-.36c-.64.03-1.11-.1-1.31-.35-.19-.26-.13-.71-.01-1.29.04-.18.06-.38.03-.59-.05-.4-.4-.7-.81-.66C5.1 1.54 1 6.04 1 11.48 1 17.28 5.75 22 11.6 22c5.02 0 9.39-3.54 10.39-8.42.08-.4-.18-.78-.58-.87Zm-9.81 7.82c-5.03 0-9.12-4.06-9.12-9.06 0-4.34 3.05-8 7.25-8.86-.08.7.05 1.33.42 1.81.24.32.66.67 1.38.84-.76 1.86-.65 3.78.36 5.11.61.81 2.03 2 4.95 1.51.18.96.71 1.54 1.18 1.87.62.43 1.38.62 2.1.62.05 0 .09 0 .13-.01-1.23 3.64-4.7 6.18-8.64 6.18ZM13 17c0 .55-.45 1-1 1s-1-.45-1-1 .45-1 1-1 1 .45 1 1Zm5.29-12.3a.99.99 0 0 1-.29-.71c0-.55.45-.99 1-.99a1 1 0 0 1 .71.3c.19.19.29.44.29.71 0 .55-.45.99-1 .99a1 1 0 0 1-.71-.3ZM9 13.5c0 .83-.67 1.5-1.5 1.5S6 14.33 6 13.5 6.67 12 7.5 12s1.5.67 1.5 1.5Zm3.25.81a.744.744 0 0 1-.06-1.05c.28-.32.75-.34 1.05-.06.31.28.33.75.05 1.06-.15.16-.35.25-.56.25-.18 0-.36-.06-.5-.19ZM8.68 7.26c.41.37.44 1 .07 1.41-.2.22-.47.33-.75.33a.96.96 0 0 1-.67-.26c-.41-.37-.44-1-.07-1.41.37-.42 1-.45 1.41-.08Zm11.48 1.88c.18-.19.52-.19.7 0 .05.04.09.1.11.16.03.06.04.12.04.19 0 .13-.05.26-.15.35-.09.1-.22.15-.35.15s-.26-.05-.35-.15a.355.355 0 0 1-.11-.16.433.433 0 0 1-.04-.19c0-.13.05-.26.15-.35Zm-4.93-1.86a.75.75 0 1 1 1.059-1.06.75.75 0 0 1-1.059 1.06Z"/></svg></button></div><script>(function(win) {
    if (!document.querySelector('.pcb')) {
        return;
    }

    var cbConfig = {
        behaviour: document.querySelector('.pcb').getAttribute('data-behaviour'),
        behaviourLink: document.querySelector('.pcb').getAttribute('data-behaviour-link'),
        revision: document.querySelector('.pcb').getAttribute('data-revision'),
        configTTL: parseInt(document.querySelector('.pcb').getAttribute('data-config-ttl'), 10),
        debugMode: document.querySelector('.pcb').getAttribute('data-debug-mode') === 'true',
        initialState: null,
        initialLsState: null,
        previouslyAccepted: []
    };

    var cbUI = {
        wrapper: document.querySelector('.pcb'),
        banner: {
            element: null,
            btnAccept: null,
            btnReject: null,
            btnConfigure: null
        },
        popup: {
            element: null,
            btnClose: null,
            btnSave: null,
            btnAccept: null,
            btnReject: null,
            checkboxes: null,
        },
        overlay: null,
        badge: null,
        blockedScripts: document.querySelectorAll('script[type^="gdpr-blocker/"]'),
        triggerLinks: cbConfig.behaviourLink ? document.querySelectorAll('a[href*="' + cbConfig.behaviourLink + '"]') : null
    };

    function initUI () {
        // setup banner elements
        cbUI.banner.element = cbUI.wrapper.querySelector('.pcb__banner');
        cbUI.banner.btnAccept = cbUI.banner.element.querySelector('.pcb__btn--accept');
        cbUI.banner.btnReject = cbUI.banner.element.querySelector('.pcb__btn--reject');
        cbUI.banner.btnConfigure = cbUI.banner.element.querySelector('.pcb__btn--configure');

        // setup popup elements
        if (cbUI.wrapper.querySelector('.pcb__popup')) {
            cbUI.popup.element = cbUI.wrapper.querySelector('.pcb__popup');
            cbUI.popup.btnClose = cbUI.wrapper.querySelector('.pcb__popup__close');
            cbUI.popup.btnSave = cbUI.popup.element.querySelector('.pcb__btn--save');
            cbUI.popup.btnAccept = cbUI.popup.element.querySelector('.pcb__btn--accept');
            cbUI.popup.btnReject = cbUI.popup.element.querySelector('.pcb__btn--reject');
            cbUI.popup.checkboxes = cbUI.popup.element.querySelector('input[type="checkbox"]');
            // setup overlay
            cbUI.overlay = cbUI.wrapper.querySelector('.pcb__overlay');
        }

        cbUI.badge = cbUI.wrapper.querySelector('.pcb__badge');

        if (cbConfig.behaviour.indexOf('link') > -1) {
            for (var i = 0; i < cbUI.triggerLinks.length; i++) {
                cbUI.triggerLinks[i].addEventListener('click', function(e) {
                    e.preventDefault();
                    showBannerOrPopup();
                });
            }
        }
    }

    function initState () {
        var lsKeyName = getConfigName();
        var currentConfig = localStorage.getItem(lsKeyName);
        var configIsFresh = checkIfConfigIsFresh();

        if (!configIsFresh || currentConfig === null) {
            if (cbConfig.debugMode) {
                console.log('ðŸª Config not found, or configuration expired');
            }

            if (window.publiiCBGCM) {
                gtag('consent', 'default', {
                    'ad_storage': window.publiiCBGCM.defaultState.ad_storage ? 'granted' : 'denied',
                    'ad_personalization': window.publiiCBGCM.defaultState.ad_personalization ? 'granted' : 'denied',
                    'ad_user_data': window.publiiCBGCM.defaultState.ad_user_data ? 'granted' : 'denied',
                    'analytics_storage': window.publiiCBGCM.defaultState.analytics_storage ? 'granted' : 'denied',
                    'personalization_storage': window.publiiCBGCM.defaultState.personalization_storage ? 'granted' : 'denied',
                    'functionality_storage': window.publiiCBGCM.defaultState.functionality_storage ? 'granted' : 'denied',
                    'security_storage': window.publiiCBGCM.defaultState.security_storage ? 'granted' : 'denied'
                });  
                
                if (cbConfig.debugMode) {
                    console.log('ðŸª GCMv2 DEFAULT STATE: ' + JSON.stringify({
                        'ad_storage': window.publiiCBGCM.defaultState.ad_storage ? 'granted' : 'denied',
                        'ad_personalization': window.publiiCBGCM.defaultState.ad_personalization ? 'granted' : 'denied',
                        'ad_user_data': window.publiiCBGCM.defaultState.ad_user_data ? 'granted' : 'denied',
                        'analytics_storage': window.publiiCBGCM.defaultState.analytics_storage ? 'granted' : 'denied',
                        'personalization_storage': window.publiiCBGCM.defaultState.personalization_storage ? 'granted' : 'denied',
                        'functionality_storage': window.publiiCBGCM.defaultState.functionality_storage ? 'granted' : 'denied',
                        'security_storage': window.publiiCBGCM.defaultState.security_storage ? 'granted' : 'denied'
                    }));
                }
            }

            showBanner();
        } else if (typeof currentConfig === 'string') {
            if (cbConfig.debugMode) {
                console.log('ðŸª Config founded');
            }

            cbConfig.initialLsState = currentConfig.split(',');

            if (window.publiiCBGCM) {
                gtag('consent', 'default', {
                    'ad_storage': getDefaultConsentState(currentConfig, 'ad_storage'),
                    'ad_personalization': getDefaultConsentState(currentConfig, 'ad_personalization'),
                    'ad_user_data': getDefaultConsentState(currentConfig, 'ad_user_data'),
                    'analytics_storage': getDefaultConsentState(currentConfig, 'analytics_storage'),
                    'personalization_storage': getDefaultConsentState(currentConfig, 'personalization_storage'),
                    'functionality_storage': getDefaultConsentState(currentConfig, 'functionality_storage'),
                    'security_storage': getDefaultConsentState(currentConfig, 'security_storage')
                });
                
                if (cbConfig.debugMode) {
                    console.log('ðŸª GCMv2 DEFAULT STATE: ' + JSON.stringify({
                        'ad_storage': getDefaultConsentState(currentConfig, 'ad_storage'),
                        'ad_personalization': getDefaultConsentState(currentConfig, 'ad_personalization'),
                        'ad_user_data': getDefaultConsentState(currentConfig, 'ad_user_data'),
                        'analytics_storage': getDefaultConsentState(currentConfig, 'analytics_storage'),
                        'personalization_storage': getDefaultConsentState(currentConfig, 'personalization_storage'),
                        'functionality_storage': getDefaultConsentState(currentConfig, 'functionality_storage'),
                        'security_storage': getDefaultConsentState(currentConfig, 'security_storage')
                    }));
                }
            }

            showBadge();

            if (cbUI.popup.element) {
                var allowedGroups = currentConfig.split(',');
                var checkedCheckboxes = cbUI.popup.element.querySelectorAll('input[type="checkbox"]:checked');

                for (var j = 0; j < checkedCheckboxes.length; j++) {
                    var name = checkedCheckboxes[j].getAttribute('data-group-name');

                    if (name && name !== '-' && allowedGroups.indexOf(name) === -1) {
                        checkedCheckboxes[j].checked = false;
                    }
                }

                for (var i = 0; i < allowedGroups.length; i++) {
                    var checkbox = cbUI.popup.element.querySelector('input[type="checkbox"][data-group-name="' + allowedGroups[i] + '"]');

                    if (checkbox) {
                        checkbox.checked = true;
                    }

                    allowCookieGroup(allowedGroups[i]);
                }
            }
        }

        setTimeout(function () {
            cbConfig.initialState = getInitialStateOfConsents();
        }, 0);
    }

    function checkIfConfigIsFresh () {
        var lastConfigSave = localStorage.getItem('publii-gdpr-cookies-config-save-date');

        if (lastConfigSave === null) {
            return false;
        }

        lastConfigSave = parseInt(lastConfigSave, 10);

        if (lastConfigSave === 0) {
            return true;
        }

        if (+new Date() - lastConfigSave < cbConfig.configTTL * 24 * 60 * 60 * 1000) {
            return true;
        }

        return false;
    }

    function getDefaultConsentState (currentConfig, consentGroup) {
        let configGroups = currentConfig.split(',');

        for (let i = 0; i < configGroups.length; i++) {
            let groupName = configGroups[i];
            let group = window.publiiCBGCM.groups.find(group => group.cookieGroup === groupName);

            if (group && group[consentGroup]) {
                return 'granted';
            }
        }  
        
        if (window.publiiCBGCM.defaultState[consentGroup]) {
            return 'granted'; 
        }
        
        return 'denied';
    }

    function initBannerEvents () {
        cbUI.banner.btnAccept.addEventListener('click', function (e) {
            e.preventDefault();
            acceptAllCookies('banner');
            showBadge();
        }, false);

        if (cbUI.banner.btnReject) {
            cbUI.banner.btnReject.addEventListener('click', function (e) {
                e.preventDefault();
                rejectAllCookies();
                showBadge();
            }, false);
        }

        if (cbUI.banner.btnConfigure) {
            cbUI.banner.btnConfigure.addEventListener('click', function (e) {
                e.preventDefault();
                hideBanner();
                showAdvancedPopup();
                showBadge();
            }, false);
        }
    }

    function initPopupEvents () {
        if (!cbUI.popup.element) {
            return;
        }

        cbUI.overlay.addEventListener('click', function (e) {
            hideAdvancedPopup();
        }, false);

        cbUI.popup.element.addEventListener('click', function (e) {
            e.stopPropagation();
        }, false);

        cbUI.popup.btnAccept.addEventListener('click', function (e) {
            e.preventDefault();
            acceptAllCookies('popup');
        }, false);

        cbUI.popup.btnReject.addEventListener('click', function (e) {
            e.preventDefault();
            rejectAllCookies();
        }, false);

        cbUI.popup.btnSave.addEventListener('click', function (e) {
            e.preventDefault();
            saveConfiguration();
        }, false);

        cbUI.popup.btnClose.addEventListener('click', function (e) {
            e.preventDefault();
            hideAdvancedPopup();
        }, false);
    }

    function initBadgeEvents () {
        if (!cbUI.badge) {
            return;
        }

        cbUI.badge.addEventListener('click', function (e) {
            showBannerOrPopup();
        }, false);
    }

    initUI();
    initState();
    initBannerEvents();
    initPopupEvents();
    initBadgeEvents();

    /**
     * API
     */
    function addScript (src, inline) {
        var newScript = document.createElement('script');

        if (src) {
            newScript.setAttribute('src', src);
        }

        if (inline) {
            newScript.text = inline;
        }

        document.body.appendChild(newScript);
    }

    function allowCookieGroup (allowedGroup) {
        var scripts = document.querySelectorAll('script[type="gdpr-blocker/' + allowedGroup + '"]');
        cbConfig.previouslyAccepted.push(allowedGroup);
    
        for (var j = 0; j < scripts.length; j++) {
            addScript(scripts[j].src, scripts[j].text);
        }

        var groupEvent = new Event('publii-cookie-banner-unblock-' + allowedGroup);
        document.body.dispatchEvent(groupEvent);
        unlockEmbeds(allowedGroup);

        if (cbConfig.debugMode) {
            console.log('ðŸª Allowed group: ' + allowedGroup);
        }

        if (window.publiiCBGCM && cbConfig.initialLsState.indexOf(allowedGroup) === -1) {
            let consentResult = {};
            let group = window.publiiCBGCM.groups.find(group => group.cookieGroup === allowedGroup);

            if (group) {
                let foundSomeConsents = false;

                Object.keys(group).forEach(key => {
                    if (key !== 'cookieGroup' && group[key] === true) {
                        consentResult[key] = 'granted';
                        foundSomeConsents = true;
                    }
                });

                if (foundSomeConsents) {
                    gtag('consent', 'update', consentResult);   

                    if (cbConfig.debugMode) {
                        console.log('ðŸª GCMv2 UPDATE: ' + JSON.stringify(consentResult));
                    }
                }
            }
        }
    }

    function showBannerOrPopup () {
        if (cbUI.popup.element) {
            showAdvancedPopup();
        } else {
            showBanner();
        }
    }

    function showAdvancedPopup () {
        cbUI.popup.element.classList.add('is-visible');
        cbUI.overlay.classList.add('is-visible');
        cbUI.popup.element.setAttribute('aria-hidden', 'false');
        cbUI.overlay.setAttribute('aria-hidden', 'false');
    }

    function hideAdvancedPopup () {
        cbUI.popup.element.classList.remove('is-visible');
        cbUI.overlay.classList.remove('is-visible');
        cbUI.popup.element.setAttribute('aria-hidden', 'true');
        cbUI.overlay.setAttribute('aria-hidden', 'true');
    }

    function showBanner () {
        cbUI.banner.element.classList.add('is-visible');
        cbUI.banner.element.setAttribute('aria-hidden', 'false');
    }

    function hideBanner () {
        cbUI.banner.element.classList.remove('is-visible');
        cbUI.banner.element.setAttribute('aria-hidden', 'true');
    }

    function showBadge () {
        if (!cbUI.badge) {
            return;
        }

        cbUI.badge.classList.add('is-visible');
        cbUI.badge.setAttribute('aria-hidden', 'false');
    }

    function getConfigName () {
        var lsKeyName = 'publii-gdpr-allowed-cookies';

        if (cbConfig.revision) {
            lsKeyName = lsKeyName + '-v' + parseInt(cbConfig.revision, 10);
        }

        return lsKeyName;
    }

    function storeConfiguration (allowedGroups) {
        var lsKeyName = getConfigName();
        var dataToStore = allowedGroups.join(',');
        localStorage.setItem(lsKeyName, dataToStore);

        if (cbConfig.configTTL === 0) {
            localStorage.setItem('publii-gdpr-cookies-config-save-date', 0);

            if (cbConfig.debugMode) {
                console.log('ðŸª Store never expiring configuration');
            }
        } else {
            localStorage.setItem('publii-gdpr-cookies-config-save-date', +new Date());
        }
    }

    function getInitialStateOfConsents () {
        if (!cbUI.popup.element) {
            return [];
        }

        var checkedGroups = cbUI.popup.element.querySelectorAll('input[type="checkbox"]:checked');
        var groups = [];

        for (var i = 0; i < checkedGroups.length; i++) {
            var allowedGroup = checkedGroups[i].getAttribute('data-group-name');

            if (allowedGroup !== '') {
                groups.push(allowedGroup);
            }
        }

        if (cbConfig.debugMode) {
            console.log('ðŸª Initial state: ' + groups.join(', '));
        }

        return groups;
    }

    function getCurrentStateOfConsents () {
        if (!cbUI.popup.element) {
            return [];
        }

        var checkedGroups = cbUI.popup.element.querySelectorAll('input[type="checkbox"]:checked');
        var groups = [];

        for (var i = 0; i < checkedGroups.length; i++) {
            var allowedGroup = checkedGroups[i].getAttribute('data-group-name');

            if (allowedGroup !== '') {
                groups.push(allowedGroup);
            }
        }

        if (cbConfig.debugMode) {
            console.log('ðŸª State to save: ' + groups.join(', '));
        }

        return groups;
    }

    function getAllGroups () {
        if (!cbUI.popup.element) {
            return [];
        }

        var checkedGroups = cbUI.popup.element.querySelectorAll('input[type="checkbox"]');
        var groups = [];

        for (var i = 0; i < checkedGroups.length; i++) {
            var allowedGroup = checkedGroups[i].getAttribute('data-group-name');

            if (allowedGroup !== '') {
                groups.push(allowedGroup);
            }
        }

        return groups;
    }

    function acceptAllCookies (source) {
        var groupsToAccept = getAllGroups();
        storeConfiguration(groupsToAccept);

        for (var i = 0; i < groupsToAccept.length; i++) {
            var group = groupsToAccept[i];

            if (cbConfig.initialState.indexOf(group) > -1 || cbConfig.previouslyAccepted.indexOf(group) > -1) {
                if (cbConfig.debugMode) {
                    console.log('ðŸª Skip previously activated group: ' + group);
                }

                continue;
            }

            allowCookieGroup(group);
        }

        if (cbUI.popup.element) {
            var checkboxesToCheck = cbUI.popup.element.querySelectorAll('input[type="checkbox"]');

            for (var j = 0; j < checkboxesToCheck.length; j++) {
                checkboxesToCheck[j].checked = true;
            }
        }

        if (cbConfig.debugMode) {
            console.log('ðŸª Accept all cookies: ', groupsToAccept.join(', '));
        }

        if (source === 'popup') {
            hideAdvancedPopup();
        } else if (source === 'banner') {
            hideBanner();
        }
    }

    function rejectAllCookies () {
        if (cbConfig.debugMode) {
            console.log('ðŸª Reject all cookies');
        }

        storeConfiguration([]);
        setTimeout(function () {
            window.location.reload();
        }, 100);
    }

    function saveConfiguration () {
        var groupsToAccept = getCurrentStateOfConsents();
        storeConfiguration(groupsToAccept);

        if (cbConfig.debugMode) {
            console.log('ðŸª Save new config: ', groupsToAccept.join(', '));
        }

        if (reloadIsNeeded(groupsToAccept)) {
            setTimeout(function () {
                window.location.reload();
            }, 100);
            return;
        }

        for (var i = 0; i < groupsToAccept.length; i++) {
            var group = groupsToAccept[i];

            if (cbConfig.initialState.indexOf(group) > -1 || cbConfig.previouslyAccepted.indexOf(group) > -1) {
                if (cbConfig.debugMode) {
                    console.log('ðŸª Skip previously activated group: ' + group);
                }

                continue;
            }

            allowCookieGroup(group);
        }

        hideAdvancedPopup();
    }

    function reloadIsNeeded (groupsToAccept) {
        // check if user rejected consent for initial groups
        var initialGroups = cbConfig.initialState;
        var previouslyAcceptedGroups = cbConfig.previouslyAccepted;
        var groupsToCheck = initialGroups.concat(previouslyAcceptedGroups);

        for (var i = 0; i < groupsToCheck.length; i++) {
            var groupToCheck = groupsToCheck[i];

            if (groupToCheck !== '' && groupsToAccept.indexOf(groupToCheck) === -1) {
                if (cbConfig.debugMode) {
                    console.log('ðŸª Reload is needed due lack of: ', groupToCheck);
                }

                return true;
            }
        }

        return false;
    }

    function unlockEmbeds (cookieGroup) {
        var iframesToUnlock = document.querySelectorAll('.pec-wrapper[data-consent-group-id="' + cookieGroup + '"]');

        for (var i = 0; i < iframesToUnlock.length; i++) {
            var iframeWrapper = iframesToUnlock[i];
            iframeWrapper.querySelector('.pec-overlay').classList.remove('is-active');
            iframeWrapper.querySelector('.pec-overlay').setAttribute('aria-hidden', 'true');
            var iframe = iframeWrapper.querySelector('iframe');
            iframe.setAttribute('src', iframe.getAttribute('data-consent-src'));
        }
    }

    win.publiiEmbedConsentGiven = function (cookieGroup) {
        // it will unlock embeds
        allowCookieGroup(cookieGroup);

        var checkbox = cbUI.popup.element.querySelector('input[type="checkbox"][data-group-name="' + cookieGroup + '"]');

        if (checkbox) {
            checkbox.checked = true;
        }

        var groupsToAccept = getCurrentStateOfConsents();
        storeConfiguration(groupsToAccept);

        if (cbConfig.debugMode) {
            console.log('ðŸª Save new config: ', groupsToAccept.join(', '));
        }
    }
})(window);</script></body></head></html>